Table 2 Inclusion and exclusion criteria

1) No prior treatment for CC.

1) Patient enrolled in a clinical trial involving an investigative new agent.

2) FIGO Stage IB2 to IVB; all histological subtypes (excluding neuro-endocrine type).

2) Co morbidity, preventing patient to tolerate the proposed standard treatment.

3) Past history of invasive cancer over the 5 years preceding entry in the present trial (except basal cell carcinoma and carcinoma in situ of the cervix).

3) Pelvic MRI available or planned before the start of treatment.

4) Possibility to communicate imaging data by CD ROM (format DICOM 3.0 or more).

4) Impossibility to carry out evaluation by MRI (patient claustrophobic, pacemaker, metallic implant, non-availability, other).

5) Patient deprived from ability to decide on her own.

5) Disease amenable to biopsy (3 tumor samples are mandatory prior to treatment).

6) Patient unable to have a regular follow up for geographical, social or psychological reasons.

6) Age ≥ 18 years.

7) Pregnancy or patient old enough to procreate and not using effective contraceptive method.

2) ECOG 0-2.

3) Life expectancy > 6 months.

4) Patient eligible for standard treatment (according to standards of each center).

5) Patient having health care insurance.

6) Informed and signed consent by patient.